Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LIPO-Liposome -- Ignore unavailable to you. Want to Upgrade?

To: KM who wrote (813)	9/16/1999 12:03:00 AM
From: Al Paxton	Respond to of 900

Link from ASCO site regarding Evacet (TLC D-99). Shows basic results and conclusion of Phase III study. Sorry can't find the full article, asco.infostreet.com The low "p-values" are a positive for Evacet. NS means "not significant". Think of "not significant" as "no evidence to suggest the results are different". NS on the top few statistics means that the EFFECTIVENESS of the combination is no different than the old method. That result was expected and Evacet never promised this. Good so far.. The low p-values next to the nasty sounding diseases says the Evacet resulted in LESS OCCURANCE of these diseases for those taking Evacet, and this result cannot be attributed to chance alone. One of the diseases has a p-value of 0.05 which is right on the border of what you would call "strongly significant". That's the only result that is borderline positive. I would say that from this summary alone there is a very good chance the drug will be recommended by the panel. It does back up the Phase II results with a larger Phase III sample. Take the last two parts off this link for other Evacet references on the ASCO site. Regards, Al